(Total Views: 716)
Posted On: 04/30/2020 10:20:11 AM
Post# of 72445
FOX Business, Innovation's Brilacidin was acknowledged today, getting mentioned, getting attention on a short list of possibilities. The citied Source: WHO, FDA news reports.
Brilacidin is earning more attention because it's progressing thru RBL trials virtually free of charge, who would've imagined this a few months ago. In life, timing is everything. While we all hate what this virus has done to wreak havoc to mankind around the world, it is a cause of celebration to see it eliminated ASAP. Could be a very effective single agent against COVID-19 when the dust settles or a very important combo agent.
If Brilacidin continues to show strong efficacy & safety in the more advanced trials at the RBL's, it will ultimately overcome all the doubters and dumpers and get the attention for partnership or a buyout. Shrewd big pharma/biotech who see and jump on the opportunity... to include B-OM, B-IBD, Kevetrin the stock will soar and could be the stock investment of the year!!!
Gilead's Remdesivir recent data (yesterday) is good progress as a single agent, not a home run, the death rate is not a great improvement vs. placebo... Maybe a Remdesivir and Brilacidin combo possibility in the future?
Brilacidin is earning more attention because it's progressing thru RBL trials virtually free of charge, who would've imagined this a few months ago. In life, timing is everything. While we all hate what this virus has done to wreak havoc to mankind around the world, it is a cause of celebration to see it eliminated ASAP. Could be a very effective single agent against COVID-19 when the dust settles or a very important combo agent.
If Brilacidin continues to show strong efficacy & safety in the more advanced trials at the RBL's, it will ultimately overcome all the doubters and dumpers and get the attention for partnership or a buyout. Shrewd big pharma/biotech who see and jump on the opportunity... to include B-OM, B-IBD, Kevetrin the stock will soar and could be the stock investment of the year!!!
Gilead's Remdesivir recent data (yesterday) is good progress as a single agent, not a home run, the death rate is not a great improvement vs. placebo... Maybe a Remdesivir and Brilacidin combo possibility in the future?
(9)
(1)
